Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

NCT04249362 ·Status: COMPLETED ·Phase: PHASE2

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT03693300 ·Status: COMPLETED ·Phase: PHASE2

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

NCT04642469 ·Status: COMPLETED ·Phase: PHASE3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

NCT05157542 ·Status: UNKNOWN ·Phase: PHASE1

Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil

NCT04948411 ·Status: COMPLETED

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461 ·Status: COMPLETED ·Phase: PHASE3

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT04513925 ·Status: COMPLETED ·Phase: PHASE3

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895 ·Status: RECRUITING ·Phase: PHASE3

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

NCT01236716 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

NCT06998719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

NCT05245994 ·Status: UNKNOWN ·Phase: PHASE2

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

NCT04622228 ·Status: COMPLETED ·Phase: PHASE2

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

NCT00662597 ·Status: TERMINATED ·Phase: PHASE3

Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC

NCT00321334 ·Status: COMPLETED ·Phase: PHASE3

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

NCT05092412 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

NCT07251582 ·Status: RECRUITING ·Phase: PHASE3

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

NCT05358691 ·Status: WITHDRAWN ·Phase: PHASE1

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

NCT03871153 ·Status: TERMINATED ·Phase: PHASE2

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection

NCT03479294 ·Status: TERMINATED

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

NCT04611776 ·Status: WITHDRAWN ·Phase: PHASE2